• Improving on "Natural" Rodent Antibodies
• 26 min
  1. The immunogenicity problem in antibody therapy

  • Prof. Herman Waldmann
• 32 min
  2. Antibodies by protein engineering

  • Prof. Sir Gregory Winter
• 60 min
  3. The generation of diversity in antibody genes

  • Prof. Michael Neuberger
• 51 min
  4. Innate immunity to retroelements by human AID/APOBEC3 proteins

  • Prof. Reuben Harris
• 36 min
  5. Fc receptors and antibody effector functions

  • Dr. Mike Clark
• 57 min
  6. Antibody engineering of Fc effector functions

  • Dr. Mike Clark
• 35 min
  7. Antibody engineering: beginnings to bispecifics and beyond

  • Dr. Ian Wilkinson
• Antibodies in Cancer Therapy
• 41 min
  8. Monoclonal antibodies and the ErbB system in human cancer

  • Prof. Mark Greene
• 71 min
  9. Checkpoint blockade in cancer immunotherapy

  • Prof. James Allison
• 45 min
  10. Monoclonal antibodies in haemato-oncology

  • Prof. Mark Cragg
• Diagnostic Antibodies
• 46 min
  11. Monitoring therapy with antibodies

  • Dr. Geoffrey Hale
• Cell Surface Glycoproteins on Cells of the Immune System
• 38 min
  12. Cell surface glycoproteins on cells of the immune system

  • Prof. Neil Barclay
• Antibodies as Immunosuppressants
• 29 min
  13. Monoclonal antibodies to induce therapeutic immunological tolerance

  • Prof. Herman Waldmann
• 29 min
  14. Antibodies to control or prevent type 1 diabetes

  • Dr. Robert Hilbrands
• 48 min
  15. Antibody therapy of multiple sclerosis

  • Dr. Alasdair Coles
  • Prof. Alastair Compston
• 42 min
  16. Monoclonal antibodies in the management of rheumatoid arthritis

  • Prof. John Isaacs
• 40 min
  17. Modern management of rheumatoid arthritis - with a focus on biologic therapies

  • Prof. John Isaacs
• 30 min
  18. Tolerance induction to clotting factors with monoclonal antibodies

  • Prof. Luis Graca
• Archived Lectures *These may not cover the latest advances in the field
• 26 min
  19. Alemtuzumab (Campath-1H) in therapy of CLL

  • Prof. Kanti Rai
• 71 min
  20. VEGF inhibitors for anti-angiogenic therapy

  • Prof. Kari Alitalo
  • Dr. Bronislaw Pytowski
• 26 min
  21. Human antibodies produced in mice

  • Dr. Marianne Bruggemann
• 52 min
  22. New strategies to prevent transplant rejection: from molecules to mice to monkeys to man

  • Prof. Christian Larsen
• 55 min
  23. CD20 antibodies in the targeting of B-cell malignancies and autoimmunity

  • Prof. Thomas Tedder
• 45 min
  24. Anti-IL-2 receptor antibodies as models for cancer therapy

  • Prof. Thomas Waldmann
• 58 min
  25. Anti TNF therapy in rheumatoid arthritis

  • Prof. Marc Feldmann
• 36 min
  26. Novel immunotherapeutic proteins: immunoligand

  • Prof. Terry Strom
• 21 min
  27. Diagnostic immunohistopathology

  • Prof. David Mason
• 56 min
  28. Antibodies in the control of type I diabetes

  • Prof. Lucienne Chatenoud
• 43 min
  29. The challenge of targeting toxins to tumors

  • Prof. Ben Seon
• 38 min
  30. Antibody depletion therapy in transplantation: implications for tolerance

  • Prof. Laurence Turka
• 36 min
  31. Antibodies as anti-virals

  • Prof. Dennis Burton

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Synopsis - RA
3. Hands of a patient with rheumatoid arthritis
4. Rheumatoid arthritis - epidemiology
5. Symptoms and signs
6. Rheumatoid arthritis pathogenesis
7. Autoimmune pathogenesis
8. Synovial histology - T cells
9. Synovial histology - B cells
10. Aims of therapy in RA
11. Synopsis - targeting T cells
12. Targeting T-cells
13. CAMPATH-1H
14. Hypothesis
15. CAMPATH-1H therapy in man
16. CD4 reconstitution
17. Case control mortality study
18. First-dose reaction
19. CAMPATH-1H first-dose reactions
20. CAMPATH-1H summary
21. Anti-CD4 therapy for RA
22. Reasons for failure of anti-T-cell therapy in man?
23. Understanding therapeutic tolerance
24. Synopsis - targeting B cells
25. B-cells as a therapeutic target in RA
26. B-cells in synovitis
27. Steps in B-cell maturation
28. CD20
29. Rituximab
30. Rituximab in RA -phase II study design
31. Rituximab phase II: Patient demographics
32. Rituximab phase II: Baseline disease characteris.
33. Rituximab phase II: ACR responses at 24 weeks
34. Rituximab phase II: ACR responses at 48 weeks
35. Summary of adverse events from phase 2 study
36. Rituximab phase II study: Circulating B-cell counts
37. Changes in total RF (median)
38. Mean IgG (up to wk 56)
39. Mean IgM (up to week 56)
40. DANCER
41. DANCER: Study design
42. DANCER: ACR response at 48 weeks
43. DANCER - Infusion reactions
44. DANCER - Conclusions
45. Effects of Rituximab treatment
46. Synopsis - costimulation blockade
47. Co-stimulation
48. CTLA4-Ig: An immunoglobulin fusion protein
49. Phase III pivotal study (AIM)
50. AIM: Clinical characteristics
51. AIM: ACR 20 response over time
52. AIM: ACR 70 response over time
53. Mean change in radiographic scores at 1 year
54. Clinically important improvement in function
55. Abatacept - summary
56. Rituximab and Abatacept
57. Synopsis - cytokine targets
58. Anti-IL6R in RA - Phase II effects
59. Anti-IL6R in RA - Phase II effects on lipids
60. Tocilizumab inhibits joint damage progression
61. Tocilizumab study - baseline
62. Tocilizumab study - outcomes
63. Summary - Tocilizumab/MRA
64. Conclusion

Topics Covered

• Background to rheumatoid arthritis
• Rheumatoid arthritis pathogenesis
• Aims of therapy in rheumatoid arthritis
• Targeting T-cells with depleting monoclonal antibodies
• Non-depleting therapies that target T-cells
• Targeting B-cells in rheumatoid arthritis
• Co-stimulation blockade
• Targeting the interleukin-6 receptor

Links

Series:

• Monoclonal Antibodies as Therapeutic Agents

Categories:

• Clinical Practice
• Immunology

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Publication History

• Published on October 1, 2007
• Reviewed on November 26, 2019

Financial Disclosures

• There are no commercial/financial matters to disclose.